Agios shareholders approve sale of oncology business to Servier

Agios Pharmaceuticals, Inc., a leader in the field of cellular metabolism to treat genetically defined diseases, announced that its shareholders voted to approve the previously disclosed sale of its commercial, clinical and research-stage oncology portfolio to Servier Pharmaceuticals, LLC, an independent global pharmaceutical company. Approximately 99.9% of the shares voted at the Special Meeting, representing approximately 90% of the outstanding shares entitled to vote, were voted in favor of the transaction. Agios will file the final vote results, as certified by the independent Inspector of Election, on a Form 8-K with the U.S. Securities and Exchange Commission. Agios expects the close of the transaction to occur around March 31, 2021, subject to the satisfaction of customary closing conditions.